Research Article | Open Access
Antimalarial Efficacy and Toxicological Assessment of Extracts of Some Ghanaian Medicinal Plants
The economic costs associated with morbidity and mortality due to malaria and malaria associated complications in many sub-Saharan countries and other malaria endemic regions of the world are huge. Reports of emergence of parasite resistance to current malaria drugs have complicated malaria treatment and require the development of new therapeutic agents. The folkloric use of medicinal plants for the management of malaria is well documented. This work evaluated the antiplasmodial activities and toxicity of some medicinal plants used to treat malaria and malaria-like symptoms in Ghana. Plant extracts were obtained by cold maceration in 70% ethanol. Antiplasmodial efficacies were assessed in vitro against 3 strains of Plasmodium falciparum strains (FCM, W2, and CAM06) and in vivo via the 4-day suppressive test in Plasmodium berghei infected mice. Cytotoxicity and acute toxicity were assessed in mammalian cells and mice, respectively. All extracts were active against at least one of the Plasmodium falciparum strains in in vitro evaluations with IC50’s in the range of 4–116 μg/mL, whereas Bidens pilosa extracts, with a chemosuppression rate of 75%, was the most active plant in the in vivo experiments. All plant extracts displayed very weak to no cytotoxicity against the mammalian cell line used and exhibited very good selectivity towards the Plasmodium parasites. Syzygium guineense and Parinari congensis extracts were the most toxic in the acute toxicity tests. Altogether, the results indicate that the medicinal plants do possess impressive antiplasmodial properties and provide scientific basis for their use in traditional herbal medicine.
Malaria is one of the major public health challenges in many countries all over the world. Over 200 million malaria cases are reported every year with more than 420,000 deaths as a result of malaria recorded annually. The malaria disease is endemic in over 90 countries, which implies about 40% of the world’s population are either affected or at risk. Most malaria morbidity and mortality are reported from sub-Saharan Africa. Ninety percent of all reported cases and deaths are from the region. In the Democratic Republic of Congo and Angola, about 34,000 and 16,000 deaths, respectively, were attributed to malaria in 2016. Reported deaths in Ghana due to malaria were estimated at about 1,300. In sub-Saharan Africa, majority of malaria victims are pregnant women and children under 5 years .
The United Nations (UN), as part of its Millennium Development Goals (MDGs), included a specific objective to address the challenges posed by malaria. This, amongst others, led to unprecedented declines in malaria morbidity and mortality in the past decade. Malaria cases and deaths dropped by more than 50% and millions of lives were saved with antimalarial drugs and vector control initiatives . In recent years, however, there has been a slow decline in the reduction rates of malaria infection. Recent reports from the World Health Organization (WHO) has revealed that the fight against malaria with available tools and funding is now at crossroads and this leaves many children and pregnant women at risk of getting the infection [1, 3].
One key challenge facing the fight against the disease is the phenomenon of drug resistance. Effective malaria control and eradication depend largely on treatment with efficacious antimalarial drugs. Antimalarial drugs such as quinine, chloroquine, and artemisinin and its derivatives have over the past years been the gold standard for treating malaria. Drug resistance, however, has led to inefficacy or reduced efficacy of these drugs [4, 5]. Despite the enormous success of artemisinin and its derivatives, in combination therapies as described by the WHO, recent reports of Plasmodium resistance in South East Asia raises an eyebrow [6, 7]. An urgent need for new and improved antimalarial therapeutics, preferably with novel routes of action to prevent, control, or minimize parasite resistance, is needed in the drug discovery pipeline. This is necessary in the event that artemisinin-resistant Plasmodium parasites become widespread throughout the world.
Indigenous use of plants as health restorative products has been around for centuries. It has been validated that remedies prepared from plants have the capacity to combat several types of diseases . According to the WHO, about 70% of the world’s population rely on herbal preparations for the treatment of diseases [9, 10]. In Ghana, herbal remedies are utilized by about 60 to 70% of the population in the rural areas  and increasingly, the urban population is also using them . The use of traditional remedies provides a cheaper, easier, and sustainable alternative to most synthetic drugs and pharmaceuticals. Additionally, they are perceived to rarely produce any side effects and are tolerated with fewer unintended consequences . It has been estimated that, of the over 1,000 medicinal plants in Ghana, about 40% are used in the treatment of various diseases such as malaria, asthma, jaundice, typhoid fever, diabetes, hypertension, and anemia [14, 15]. In Ghana, 6% of medicinal plants on the domestic market are used in malaria and fever management . Many of these plants have been formulated as registered commercial products and are available to the public as malaria therapeutic agents. A key challenge in the use of medicinal plants in malaria treatment is the absence of scientific evidence of their efficacies. Additionally, toxicological profiles of these plants are either missing or scanty at best. In this study, 11 medicinal plants that are ethnomedically used in the treatment of malaria and malaria-like symptoms in Ghana were investigated for their antiplasmodial activities and toxicity profiles. Crude ethanolic extracts from these plants was tested in vitro against three different strains of the Plasmodium parasite: Plasmodium falciparum chloroquine-sensitive (FCB), Plasmodium falciparum chloroquine-resistant (W2), and a field isolate (coded as CAM06, obtained from a local patient). In vivo antiplasmodial activity (4-day suppressive tests) was evaluated in Plasmodium berghei infected BALB/C mice. The ethanolic extracts were also assessed for cytotoxicity (against LLC-MK2 monkey kidney epithelial cells) and acute toxicity (in mice).
2.1. Collection of Plant Material
Eleven plants ethnomedically used for the treatment of malaria and malaria-like symptoms in Ghana were selected for this work. The plant sample was collected from various parts of Ghana between August and December 2017 and was identified and authenticated by Mr. Clifford Asare, a plant botanist at the Department of Herbal Medicine, Faculty of Pharmacy and Pharmaceutical Sciences at the Kwame Nkrumah University of Science and Technology (KNUST). Specimens with voucher numbers were deposited in the herbarium. Harvested plant materials were washed under running water to remover foreign matter. Plant materials were air-dried at ambient temperatures under a shade for up to 2 weeks, depending on plant part, and pulverized into course powders. Table 1 describes the parts of the various plants used for the study and their local indications.
Antiplasmodial activity reports exist in literature. Extract yield based on dry-powdered plant material.
One hundred grams of each powdered plant material was macerated in 70% ethanol for a minimum of 5 days. The residue was separated from the menstruum via filtration and concentrated in vacuo (Cole Parmer Rotary Evaporator N-1110, China). They were then transferred into screw-capped vials and stored at C until use.
2.3. Phytochemical Analysis
2.4. In Vitro Antiplasmodial Activity
The plant extracts were assayed against Plasmodium falciparum chloroquine-sensitive (FCB), P. falciparum chloroquine-resistant (W2), and a P. falciparum field isolate (coded CAM06, obtained from local patients) strains using the lactate dehydrogenase (pLDH) method previously described by  and modified by [23, 24]. Parasites were cultured in vitro according to the method of . Parasites were grown in uninfected O+ human red blood cells as host cells and maintained in RPMI 1640 containing 2.5% hematocrit, hypoxanthine (0.5 × 100−2% w/v), HEPES (59.4 × 100−2% w/v), glucose (0.25 × 100−2% w/v), and albuMAX II (50.0 × 100−2% w/v), and buffered with NaHCO3 to a pH of 7.34. Fresh culture was maintained for at least 96 hours (2 complete life cycles) before being used for assays. All solutions were filter-sterilized with 0.22 μm syringe-adapted filters (Corning®, NY, USA). Assays were performed in 96-well culture plates and all IC50 values were obtained from dose-response curves.
2.5. In Vitro Cytotoxicity
Cytotoxicity was evaluated on LLC-MK2 monkey kidney epithelial cells. Cells were grown in DMEM culture medium supplemented with 10% fecal bovine serum (FBS, Life Technologies) and 1% penicillin/streptomycin. Trypsinated cells were distributed in 96-well microtiter plates at 10,000 cells in 100 μL per well and incubated for 48 hours to allow them to attach before adding the extracts. After 48 hours, the medium was removed completely from each well, and 100 μL of fresh culture medium was added. Thereafter, 100 μL of crude extracts (400 μg/mL) was added and then serially diluted. Cells without drug/extract addition (100% growth) served as controls. The cells with or without extracts were incubated at C in 5% , 5% , and 90% N2 incubator for 72 h before determining their viability. Each concentration was tested in triplicate. Cell viability was determined by MTT assay and the cytotoxic activity was determined as described elsewhere [24, 26]. The percentage viability and percentage mortality were calculated from the OD values using Microsoft Excel. The mean results of the percentage mortality were plotted against the logarithms of concentrations using GraphPad Prism. Regression equations obtained from the graphs were used to calculate cytotoxic concentration fifty (CC50), which is the concentration of extract required to kill fifty percent of the cells. The selective index (SI) was computed as the ratio of CC50 to IC50 value.
2.6. In Vivo Acute Toxicity
This was done through assessment of the acute toxicity of the extracts, using male Balb/C mice, according to Organization for Economic Cooperation and Development (OECD) guidelines for testing of chemicals acute oral toxicity . Healthy young adult male mice aged 8-10 weeks (18-30 g body weight) were used. In brief, for each extract, animals were randomly divided into groups of 5 animals each. A control group was maintained without any treatment (receiving only the vehicle). The animals in all the experimental groups were kept in their respective cages for 5 days for acclimatization prior to the start of the experiment. Animals in the eleven test groups received plant extract at a fixed dose of 5000 mg/kg, while those of the control group were administered the vehicle (distilled water). Animals were fasted 4 hours prior to dosing and 2 hours after dosing with extract or vehicle, while water was made available throughout the experiment. Apart from these exceptions, the animals also received feed ad libitum throughout the experiment. The mice were observed periodically for 4 hours following administration of extract/vehicle and every day for 14 days for detection of mortality as well as any behavioral alterations. Feed and water consumption were monitored. Body weight was also recorded on days 7 and 14 .
2.7. In Vivo Antiplasmodial Activity
The in vivo antiplasmodial activities of the extracts with significant in vitro antiplasmodial activity were evaluated via the 4-day suppressive test against Plasmodium berghei infections in mice. Extracts were prepared by dissolving 5 mg dry crude extracts in 200 μL DMSO (Sigma, MO, USA) and then diluted with distilled water to the desired concentration.
2.7.1. Animal and Parasite
BALB/C mice (Male and Female) of age 6–8 weeks and weight 27–32 g were maintained at a temperature of C and a 12-hour light/12-hour dark cycle, with food and water given ad libitum in the Animal House of MRABL at the Faculty of Health Sciences, University of Buea, Cameroon. All experiments were conducted in accordance with internationally accepted laboratory animal use.
2.7.2. Parasite Inoculation
Donor albino mice previously infected with Plasmodium berghei and having parasitemia level of 20-30% were used. The donor mice were anesthetized and sacrificed by opening the thoracic region in order to expose the heart. Blood was collected by cardiac puncture into heparinized vacutainer tube containing 0.5% trisodium citrate. Physiological saline (0.9%) was used to dilute the blood based on the parasitemia level of the donor mice [28, 29]
2.7.3. Suppressive Test
The 4-day suppressive test was used to evaluate the in vivo schizonticidal activity of three of the plants (Bidens pilosa, Paspalum scrobiculatum, and Clappertonia ficifolia) against Plasmodium berghei infected BALB/C mice following reported methods [28, 30] with some modifications. Briefly, infected mice were randomly divided into four groups of 5 each by weight. Treatment started three hours after mice have been inoculated with parasite on day 0 and continued for four days (day zero inclusive). For each extract, animals received daily oral dose of 400 mg kg−1 day−1 in 100 μL vehicle (2% DMSO in distilled water). A positive control-group received 10 mg/kg weight quinine per day, while the negative-control group animals were administered 100 μL of the vehicle. On the 4th day after treatment, blood sample was obtained from the tail of each mouse. A thin film was prepared and stained with Giemsa to determine parasitemia levels. The mean parasitemia in each group was determined and the % chemosuppression of each sample was computed as [(A – B)/A] x 100, where was the mean parasitemia in the negative control group and was the mean parasitemia in the test group.
In this study, the antiplasmodial activities of 11 medicinal plants commonly used in Ghana for malaria treatment were evaluated in both in vitro and in vivo assays. Additionally, the cytotoxicity of the plant extracts towards mammalian cell lines and acute toxicity in mice models were also assessed. The 11 plants chosen for this study were obtained from informal discussions with local traditional healers, indigenes, and literature search. The 11 plants belonged to different families and are used in treating ailments such as fever, malaria, stomach aches, and infections. Plant extracts were obtained by cold maceration in 70% ethanol. The yields of the extraction ranged from 5.0 to 15.0% (Table 1).
Phytochemical screening for the major chemical classes revealed the presence of tannins, steroids, flavonoids, alkaloids, coumarins, and glycosides which may be responsible for the observed antiplasmodial activities, as shown in Table 2. The ubiquitous phytochemical, tannin, was present in all plant samples investigated in this study, whereas alkaloids were absent in all plants except Faurea speciosa. Steroids, flavonoids, coumarins, and glycosides were present in at least 5 plant samples. None of the plants studied contained all six phytochemicals tested for. In Paspalum scrobiculatum, the only phytochemical present was tannins.
(-) Absent; (+) present; and (++) strongly present.
To determine the in vitro antiplasmodial activity, plant extracts were screened against the schizont stage of 3 different strains of the Plasmodium falciparum parasite: chloroquine-sensitive (FCB), chloroquine-resistant (W2), and CAM06, a field isolate. Table 3 shows the IC50 of the extracts against the 3 Plasmodium falciparum strains. The guidelines of Jonville et al.  that classify antiplasmodial activity as high (IC50 <5 μg/mL), promising (5 < IC50 <15 μg/mL), moderate (15 < IC50 < 50 μg/mL), and inactive (IC50 > 50 μg/mL) were adopted for classification of the potency of the various extracts. At low concentrations, inhibition of parasite indicates selective activity, while action at high concentrations may be as a result of nonspecific toxicity. When tested against the chloroquine sensitive FCB strain, Clappertonia ficifolia (4.43 ± 0.18 μg/mL) was the only extract that exhibited high antiplasmodial activity. Six other extracts showed promising activities with another 3 showing moderate activity. Acridocarpus alternifolius, with an IC50 of 175.89 ± 0.37 μg/mL, was inactive. Against the chloroquine-resistant W2 strain, Bidens pilosa (4.60 ± 0.91 μg/mL) and Syzygium guineense (4.62 ± 1.14 μg/mL) were the most active extracts. Clappertonia ficifolia exhibited promising antiplasmodial activity against W2, with an IC50 of 7.94 ± 1.36 μg/mL. None of the extracts exhibited high activity towards CAM06. Clappertonia ficifolia, Faurea speciosa, Syzygium guineense, and Croton penduliflorus, however, had promising activities. Against all strains tested, Clappertonia ficifolia was most potent, with IC50’s less than 10 μg/mL in all cases. Faurea speciosa and Syzygium guineense had IC50’s less than 15 μg/mL and were also very active.
Concentration of extract that kills 50% of Plasmodium falciparum.
According to , high (μg/mL), promising (μg/mL), moderate (μg/mL), and inactive (μg/mL).
Following the in vitro antiplasmodial tests, the extracts were screened against a mammalian cell line (LLC-MK2 monkey kidney epithelial cells) to evaluate cytotoxicity. The extract concentration that was cytotoxic to 50% of the cells (CC50) ranged from 77.9 to >1,000 μg/mL (Table 4). The most cytotoxic extract was Syzygium guineense with a CC50 of 77.9 ± 0.71 μg/mL. Extracts of Acridocarpus alternifolius and Datura stramonium were the least toxic to the mammalian cells, with CC50 values above 1,000 μg/mL. The selectivity index (SI) of Paspalum scrobiculatum, Bidens pilosa, and Syzygium guineense extracts towards FCB strain of P. falciparum were all < 10 indicating minimal selectivity (Table 4). Datura stramonium extract had a much higher selectivity towards the FCB strain relative to the mammalian cell lines used. Parinari congensis and Monanthotaxis caffra had SI values < 10 for both CAM06 and W2 strains. Paspalum scrobiculatum and Bidens pilosa also had SI values < 10 for the field strain CAM06.
CC50, = cytotoxic concentration 50%.
Mean and standard deviation values of CC50 were generated from three replicate experiments.
CC50 < 5: highly toxic; 5 < CC50 <10: cytotoxic; 10 < CC50 < 30: moderately to weakly cytotoxic; and CC50 > 30: noncytotoxic .
In the acute toxicity test, 5000 mg of extract per kg body weight of mice was administered. Upon administration, one animal dead (representing 20%) was recorded in Syzygium guineense and Parinari congensis during the first 16 hours and 24 hours, respectively. In addition, animals in these two groups were very sluggish at the beginning of the observation period and recovered significantly only after 24 hours. The growth pattern of mice treated with control or extracts were very similar. In virtually all the groups, a weight increase was observed between day 1 and day 14. Figure 1 illustrates the changes in weight of the various treatment groups over the 2-week period.
Three of the extracts that showed appreciable antiplasmodial activities in vitro and are commonly used in Ghana (i.e., have significant traditional importance) were evaluated for in vivo antiplasmodial activity using the 4-day suppressive test and the results are summarized in Table 5. There was substantial decrease in percentage parasitemia for all extract treatment groups in comparison to the negative control. Maximal suppression of parasitemia was observed in Bidens pilosa treatment groups with a percent chemosuppression of 74.73. All extracts were however inferior to quinine, which recorded a chemosuppression of 90.22%.
Plant medicines have been a source of novel therapeutic agents for various ailments. Two of the most important antimalarial drugs, artemisinin and quinine, originated from Artemisia annua and Cinchona officinalis, respectively . Plant medicines also play a critical role in primary health care for most of the world’s population, especially in malaria treatment . Unfortunately, scientific validation for the use of most of these medicines is absent and represents a major challenge in the industry . This study evaluated the antiplasmodial potential of 11 medicinal plants used for the treatment of malaria and malaria-like symptoms in Ghana. A number of chemical classes of plant origin have been shown to be potential antiplasmodial agents. Alkaloids, terpenes, flavonoids, coumarins, and limonoids are some examples [31, 33]. Phytochemicals may act alone or in synergy with other phytoconstituents to elicit the observed biological activities. It has been reported that alkaloids, flavonoids, and sesquiterpenes are, in general, potent secondary metabolites of plants that display broad-spectrum biological activities . The extracts investigated in this study possessed some of these phytochemicals and may be the reason for the observed antiplasmodial activities.
Of the plants selected for this study, the antiplasmodial activity of 3 plants is present in the literature. The antiplasmodial activities of Bidens pilosa have been reported by researchers in Africa and Brazil. A research team in Brazil  reported that 50 μg/mL of the ethanol and chloroform extracts of the leaf and stem parts of Bidens pilosa inhibited P. falciparum growth by 90%. Similarly,  reported an inhibition of parasite growth by 45% with ethyl acetate extracts of the same plant. In 2004, Clarkson and coworkers reported an IC50 of 5 μg/mL and 70 μg/mL for methanol and water extracts, respectively . In our study, Bidens pilosa extracts showed very high activity against the chloroquine-resistant W2 strain, in agreement with earlier reports. Moderate activity was however observed towards the chloroquine-sensitive (FCB) and field strains (CAM06) of P. falciparum. The antiplasmodial activities of the root parts of Bidens pilosa have been attributed to the presence of polyacetylene and flavonoids . The leaf extracts used in this study tested positive for flavonoids and may also be responsible for the high activity. Mitragyna ciliata extracts showed moderate antiplasmodial activity towards all 3 P. falciparum strains tested in this study, in agreement with a study conducted in 2007 where IC50 values ranged between 10 and 44 μg/mL for various solvent extracts . On the contrary, another study reported antiplasmodial activities with IC50 values above 100 μg/mL . The similarity in activities between this study and that of Adjetey and colleagues  may lie in the use of similar solvent systems in both studies for extraction. Interestingly, it was also reported that M. ciliata extract was able to modulate chloroquine activity by reversing resistance in a chloroquine-resistant strain . The leaf extract of Syzygium guineense showed high antiplasmodial activity in vitro against W2 and CAM06. The antiplasmodial activity of Syzygium guineense has also been reported, but only in an in vivo model where 49% chemosuppression was observed upon administration of 400 mg/kg of extract to a rodent .
The antiplasmodial activities of 8 of the plants used in this study have been reported for the first time. These 8 plants are Paspalum scrobiculatum, Acridocarpus alternifolius, Clappertonia ficifolia, Parinari congensis, Monanthotaxis caffra, Datura stramonium, Faurea speciosa, and Croton penduliflorus. Acridocarpus alternifolius showed no antiplasmodial activity towards FCB and CAM06 strains of P. falciparum tested with IC50’s above 50 μg/mL and showed only moderate activity towards W2 strain. Datura stramonium was also inactive towards W2 but showed moderate activity when tested against CAM06 and promising activity towards the chloroquine sensitive FCB strain. Although no antiplasmodial activity of Datura stramonium extracts exists in the literature, reports of the antiplasmodial activity of other Datura species exist. Datura metel has been reported to be active against both chloroquine-sensitive and chloroquine-resistant strains of the Plasmodium parasite [42, 43]. Other biological activities of Datura stramonium such as antioxidant and cytotoxicity however exist [44, 45].
Parinari congensis also showed promising antiplasmodial activity towards the chloroquine-sensitive FCB strain, marginally moderate activity towards CAM06 and inactivity towards W2 strain. Extracts of Parinari congensis have been shown to possess antioxidant, anti-inflammatory, and diabetic modulating properties [46–48]. Croton penduliflorus showed promising activity towards all P. falciparum strains tested, whereas Monanthotaxis caffra showed moderate activities towards W2 and CAM06 strains but had promising activity towards the chloroquine-sensitive FCB strain. Other than tannins, the two extracts had little in common in terms of phytochemical profiles. Although no antiplasmodial activity record of Monanthotaxis caffra exists, it has been reported that extracts and compounds obtained from Monanthotaxis parvifolia exhibited good antiplasmodial activities [49, 50]. Paspalum scrobiculatum and Faurea speciosa showed promising to moderate antiplasmodial activities against all 3 strains. Paspalum scrobiculatum was most active towards W2, whereas Faurea speciosa showed greater activity towards CAM06. Clappertonia ficifolia proved to be one of the most active extracts amongst the plants studied. IC50 values against all strains of parasites tested were well below 10 μg/mL. In particular, high activity was observed against FCB with an IC50 of 4.43 μg/mL.
For cytotoxicity, the extracts CC50 values were all above 30 μg/mL. Extracts of Syzygium guineense and Monanthotaxis caffra were the most toxic to the LLC-MK2 cells, with CC50 values below 100 μg/mL. All extracts were non-cytotoxic at the concentrations tested . Clappertonia ficifolia, which exhibited very good antiplasmodial activities, also had high SI towards all 3 strains (SI > 30), indicating that the extract is selective towards the parasites. Paspalum scrobiculatum and Bidens pilosa also showed good selectivity towards the chloroquine-resistant W2 strain.
In the acute toxicity, even though one death each was recorded on the first day in treatment groups that received extracts from Syzygium guineense and Parinari congensis, LD50 for these extracts are above 5000 mg/kg, as indicated in the OECD guidelines. No mortality was recorded for all other treatment groups over the 14 days of observation. The increase in weight in all the test groups during the duration of the experiment indicates absence of or low toxicity. Changes in body weight gain are a simple and sensitive index of toxicity after an animal has been exposed to a toxic constituent .
The in vivo antiplasmodial results indicated that Bidens pilosa, at a dosage of 400 mg/kg, possessed a chemosuppression rate of 74.73%. This agrees with an earlier report of a chemosuppression rate of 36% at 250 mg/kg, which is about half the dosage used for this study . Clappertonia ficifolia and Paspalum scrobiculatum also showed good chemosuppression rates. The results of the in vitro and in vivo antiplasmodial tests of Clappertonia ficifolia and Paspalum scrobiculatum extracts reveal that these extracts may contain compounds that when isolated could be useful in malaria drug discovery. The results also validate their use in traditional medicine for management of malaria.
The results of this study confirm the traditional use of these medicinal plants for the treatment of malaria and malaria-like symptoms. The toxicological results obtained suggest a need for a routine evaluation of medicinal plants to establish any toxicity before administration. Isolation of the active constituents from the most active plants is ongoing in our laboratories.
The data used to support the findings of this study are included within the article.
The project proposal and procedures were reviewed and approved by the Institution Ethics Review Board for Animal Use at the University of Buea, Cameroon.
Conflicts of Interest
All authors declare no competing financial, professional, or personal interests that might have influenced the performance or presentation of the work described in this manuscript.
Lawrence Sheringham Borquaye and Michael Konney Laryea conceived the study. All experiments were designed by Lawrence Sheringham Borquaye and Michael Konney Laryea. Plant materials were collected by Michael Konney Laryea. Michael Konney Laryea carried out all the experiments. Data analysis was carried out by Michael Konney Laryea and Lawrence Sheringham Borquaye. The manuscript was prepared by Lawrence Sheringham Borquaye and Michael Konney Laryea. All authors read and approved the final manuscript.
The authors are grateful to the Department of Chemistry, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana, and the Medical Research & Applied Biochemistry Laboratory, University of Buea, Cameroon, for the use of its facilities for this study. They are also grateful to Dr. Denis Zofou of the Medical Research & Applied Biochemistry Laboratory, University of Buea, Cameroon, for helpful discussions. Mr. Clifford Asare of the Department of Herbal Medicine, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana, is also acknowledged for his help in obtaining plant samples and authentication. Funding for this work was provided by an International Foundation for Science (IFS) Collaborative Research Grant (J/5748-1) to Lawrence Sheringham Borquaye.
- WHO, World Malaria Report 2015, World Health Organization, Geneva, Switzerland, 2015.
- WHO, Achieving the Malaria MDG Target: Reversing the Incidence of Malaria 2000–2015, World Health Organization, Geneva, Switzerland, 2015.
- G. Benelli and H. Mehlhorn, “Declining malaria, rising of dengue and Zika virus: insights for mosquito vector control,” Parasitology Research, vol. 115, no. 5, pp. 1747–1754, 2016.
- B. Hanboonkunupakarn and N. J. White, “The treat of antimalarial drug resistance,” Tropical Diseases, Travel Medicine and Vaccines, vol. 2, no. 1, p. 10, 2016.
- WHO, World Malaria Report 2011, World Health Organization, Geneva, Switzerland, 2012.
- A. P. Phyo, S. Nkhoma, K. Stepniewska et al., “Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study,” The Lancet, vol. 379, no. 9830, pp. 1960–1966, 2012.
- H. Noedl, Y. Se, K. Schaecher, B. L. Smith, D. Socheat, and M. M. Fukuda, “Evidence of artemisinin-resistant malaria in Western Cambodia,” The New England Journal of Medicine, vol. 359, no. 24, pp. 2619-2620, 2008.
- F. Firenzuoli and L. Gori, “Herbal medicine today: clinical and research issues,” Evidence-Based Complementary and Alternative Medicine, vol. 4, supplement 1, pp. 37–40, 2007.
- N. Mamedov, “Medicinal plants studies: history, challenges and prospective,” Medicinal & Aromatic Plants, vol. 01, no. 08, 2012.
- WHO, National Policy on Traditional Medicine and Regulation of Herbal Medicines: Report of a WHO Global Survey, World Health Organization, Geneva, Switzerland, 2005.
- A. Asase, A. A. Oteng-Yeboah, G. T. Odamtten, and M. S. J. Simmonds, “Ethnobotanical study of some Ghanaian anti-malarial plants,” Journal of Ethnopharmacology, vol. 99, no. 2, pp. 273–279, 2005.
- G. Komlaga, C. Agyare, R. A. Dickson et al., “Medicinal plants and finished marketed herbal products used in the treatment of malaria in the Ashanti region, Ghana,” Journal of Ethnopharmacology, vol. 172, pp. 333–346, 2015.
- H. Nasri and H. Shirzad, “Toxicity and safety of medicinal plants,” Journal of Herbmed Pharmacology, vol. 2, no. 2, pp. 21-22, 2013.
- D. Abbiw, “Food and Fodder,” in Useful Plants of Ghana, pp. 22–58, Practical Action Publishing, 1990.
- T. A. Van, B. Myren, and S. O. Van, “Ghana's herbal market,” Journal of Ethnopharmacology, vol. 140, no. 2, pp. 368–378, 2012.
- M. Jonville, H. Kodja, L. Humeau et al., “Screening of medicinal plants from Reunion Island for antimalarial and cytotoxic activity,” Journal of Ethnopharmacology, vol. 120, no. 3, pp. 382–386, 2008.
- H. Malebo, W. Tanja, M. Cal et al., “Antiplasmodial, anti-trypanosomal, anti-leishmanial and cytotoxicity activity of selected Tanzanian medicinal plants,” Tanzania Journal of Health Research, vol. 11, no. 4, 2009.
- M. M. Adia, S. N. Emami, R. Byamukama, I. Faye, and A. Borg-Karlson, “Antiplasmodial activity and phytochemical analysis of extracts from selected Ugandan medicinal plants,” Journal of Ethnopharmacology, vol. 186, pp. 14–19, 2016.
- W. C. Evans, Trease and Evans Pharmacognosy, Saunders, Edinburgh, Scotland, 15th edition, 2002.
- A. Sofowora, Medicinal Plants and Traditional Medicine in Africa, Spectrum Books Limited, Ibadan, Nigeria, 1993.
- A. J. Harborne, Phytochemical Methods: A Guide to Modern Techniques of Plant Analysis, Springer Science & Business Media, 1998.
- D. J. Hinrichs and M. T. Makler, “Measurement of the lactate dehydrogenase activity of plasmodium falciparum as an assessment of parasitemia,” The American Journal of Tropical Medicine and Hygiene, vol. 48, no. 2, pp. 205–210, 1993.
- E. Tuenter, K. Segers, K. Kang et al., “Antiplasmodial activity, cytotoxicity and structure-activity relationship study of cyclopeptide alkaloids,” Molecules, vol. 22, no. 2, p. 224, 2017.
- D. Zofou, M. Tene, M. N. Ngemenya, P. Tane, and V. P. K. Titanji, “In vitro antiplasmodial activity and cytotoxicity of extracts of selected medicinal plants used bytraditional healers of Western Cameroon,” Malaria Research and Treatment, vol. 2011, Article ID 561342, 6 pages, 2011.
- W. Trager and J. B. Jensen, “Human malaria parasites in continuous culture,” Science, vol. 193, no. 4254, pp. 673–675, 1976.
- R. S. Nondo, M. J. Moshi, P. Erasto et al., “Anti-plasmodial activity of Norcaesalpin D and extracts of four medicinal plants used traditionally for treatment of malaria,” BMC Complementary and Alternative Medicine, vol. 17, no. 1, p. 167, 2017.
- OECD, OECD Guideline For Testing Of Chemicals Acute Oral Toxicity–Acute Toxic Class Method Adopted, 2001.
- A. Nardos and E. Makonnen, “In vivo antiplasmodial activity and toxicological assessment of hydroethanolic crude extract of Ajuga remota,” Malaria Journal, vol. 16, no. 1, article no. 25, 2017.
- P. J. Waako, B. Gumede, P. Smith, and P. I. Folb, “The in vitro and in vivo antimalarial activity of Cardiospermum halicacabum L. and Momordica foetida Schumch. Et Thonn,” Journal of Ethnopharmacology, vol. 99, no. 1, pp. 137–143, 2005.
- W. Peters, J. H. Portus, and B. L. Robinson, “The chemotherapy of rodent malaria, XXII,” Annals of Tropical Medicine and Parasitology, vol. 69, no. 2, pp. 155–171, 1975.
- S. Schwikkard and F. R. van Heerden, “Antimalarial activity of plant metabolites,” Natural Product Reports, vol. 19, no. 6, pp. 675–692, 2002.
- M. Angell and J. P. Kassirer, “Alternative medicine—the risks of untested and unregulated remedies,” The New England Journal of Medicine, vol. 339, no. 12, pp. 839–841, 1998.
- H. Kaur, H. M. Mukhtar, A. Singh, and A. Mahajan, “Antiplasmodial medicinal plants: a literature review on efficacy, selectivity and phytochemistry of crude plant extracts,” Journal of Biologically Active Products from Nature, vol. 8, no. 5, pp. 272–294, 2018.
- S. Saxena, N. Pant, D. C. Jain, and R. S. Bhakuni, “Antimalarial agents from plant sources,” Current Science, vol. 85, no. 9, pp. 1314–1329, 2003.
- M. Brandão, A. Krettli, L. Soares, C. Nery, and H. Marinuzzi, “Antimalarial activity of extracts and fractions from Bidens pilosa and other Bidens species (Asteraceae) correlated with the presence of acetylene and flavonoid compounds,” Journal of Ethnopharmacology, vol. 57, no. 2, pp. 131–138, 1997.
- D. Lacroix, S. Prado, D. Kamoga et al., “Antiplasmodial and cytotoxic activities of medicinal plants traditionally used in the village of Kiohima, Uganda,” Journal of Ethnopharmacology, vol. 133, no. 2, pp. 850–855, 2011.
- C. Clarkson, V. J. Maharaj, N. R. Crouch et al., “In vitro antiplasmodial activity of medicinal plants native to or naturalised in South Africa,” Journal of Ethnopharmacology, vol. 92, no. 2-3, pp. 177–191, 2004.
- F. Oliveira, V. Andrade-Neto, A. Krettli, and M. Brandão, “New evidences of antimalarial activity of Bidens pilosa roots extract correlated with polyacetylene and flavonoids,” Journal of Ethnopharmacology, vol. 93, no. 1, pp. 39–42, 2004.
- T. A. Adjétey, M. K. Djè, M. Vangah-Manda et al., “Antimalarial activity of Mitragyna ciliata (Aubrev and Pellegr) (Rubiaceae): Preliminary study,” South African Journal of Botany, vol. 73, no. 2, pp. 226–229, 2007.
- H. Ménan, J.-T. Banzouzi, A. Hocquette et al., “Antiplasmodial activity and cytotoxicity of plants used in West African traditional medicine for the treatment of malaria,” Journal of Ethnopharmacology, vol. 105, no. 1-2, pp. 131–136, 2006.
- S. A. Tadesse and Z. B. Wubneh, “Antimalarial activity of Syzygium guineense during early and established Plasmodium infection in rodent models,” BMC Complementary and Alternative Medicine, vol. 17, no. 1, p. 21, 2017.
- K. Chenniappan and M. Kadarkarai, “In vitro antimalarial activity of traditionally used Western Ghats plants from India and their interactions with chloroquine against chloroquine-resistant Plasmodium falciparum,” Parasitology Research, vol. 107, no. 6, pp. 1351–1364, 2010.
- C. Kamaraj, N. K. Kaushik, A. A. Rahuman et al., “Antimalarial activities of medicinal plants traditionally used in the villages of Dharmapuri regions of South India,” Journal of Ethnopharmacology, vol. 141, no. 3, pp. 796–802, 2012.
- I. M. Ahmad, M. Y. Abdalla, N. H. Mustafa, E. Y. Qnais, and F. A. Abdulla, “Datura aqueous leaf extract enhances cytotoxicity via metabolic oxidative stress on different human cancer cells,” Jordan Journal of Biological Sciences, vol. 2, no. 1, pp. 9–14, 2009.
- N. A. Spiridonov, D. A. Konovalov, and V. V. Arkhipov, “Cytotoxicity of some Russian ethnomedicinal plants and plant compounds,” Phytotherapy Research, vol. 19, no. 5, pp. 428–432, 2005.
- A. Dokubo, A. A. Uwakwe, and B. A. Amadi, “A study on the antioxidant and anti-inflammatory effects of aframomum sceptrum and parinari congensis seed extracts in alloxan-induced diabetic wistar rats,” EPRA International Journal of Research & Development, vol. 2, no. 7, pp. 1–9, 2017.
- A. Dokubo, A. A. Uwakwe, and B. A. Amadi, “Effects of aframomum sceptrum and parinari congensis seed extracts in alloxan induced-diabetic wistar albino rats,” International Journal of Geology and Earth Sciences, vol. 3, no. 5, pp. 20–33, 2017.
- M. Tchicaillat-Landou, J. Petit, C. Gaiani et al., “Ethnobotanical study of medicinal plants used by traditional healers for the treatment of oxidative stress-related diseases in the Congo Basin,” Journal of Herbal Medicine, vol. 13, pp. 76–90, 2018.
- N. N. Mungai, I. O. Kibwage, J. W. Mwangi et al., “Isolation, characterization and antiplasmodial activity of phytochemical constituents from Monanthotaxis parvifolia (Oliv.) Verdc ssp. kenyensis Verdc,” East and Central African Journal of Pharmaceutical Sciences, vol. 17, no. 3, pp. 87–93, 2014.
- N. N. Mungai, Antiplasmodial and phytochemical investigation of monanthotaxis parvifolia (oliv.) verdc ssp. Kenyensis verdc (annonaceae), [Ph.D. thesis], University of Nairobi, Nairobi, Kenya, 2015.
Copyright © 2019 Michael Konney Laryea and Lawrence Sheringham Borquaye. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.